One concrete data point for the thread. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.
Worth separating that from the trial evidence, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
One thing that is still open after sophie_paris’s answer:
How to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases?
PharmacoVig_BOS said:A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator.
Coming at PharmacoVig_BOS’s question from a different direction. Read four things before the headline number. The population, because trial populations are selected and supported in ways that real cohorts are not. The comparator, because "better than placebo" and "better than the current standard" are different claims and get reported identically. The primary endpoint as pre-registered, because a secondary endpoint promoted after the fact is a hypothesis rather than a finding. And the completion rate, because a large effect in the half of participants who finished is a different result from a large effect in everybody enrolled.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOP back with an update, since a thread like this is useless without one.
Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have. That was reassuring rather than otherwise.
Dr.BariatricHTX said:Read four things before the headline number.
Peptide degradation indicators for injection-site reactions — how to know if your medication has gone bad:
- Visual: cloudiness, particles, color change (should be clear and colorless)
- Tactile: unusual resistance when drawing up (viscosity change)
- Efficacy: sudden loss of appetite suppression with same dose
- Side effects: unexpected injection site reactions
If any of these occur, stop using the vial and open a fresh one. Document the issue and report to your pharmacy. Degraded peptides are at best ineffective, at worst potentially harmful due to degradation products.